Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

esigns, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking st
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014   Santa Clara dentist ... a special promotion for Invisalign. Invisalign is an orthodontic ... wires. It is often the orthodontic treatment of choice ... and aesthetics of it. For a limited time, patients ... significant savings from the usual cost. This offer cannot ...
(Date:9/2/2014)... 2, 2014 ... bij het ESC CONGRESS 2014 geven inzicht ... risico op beroerte in de dagelijkse klinische ... bijna 12.500 patiënten ingeschreven in de Global ... een innovatief, onafhankelijk initiatief op het gebied ...
(Date:9/2/2014)... According to the new market research report ... Material (Metal, Glass, Plastic), by Application [GC, LC (HPLC, ... by MarketsandMarkets, the Chiral Chromatography Columns Market was valued ... at a CAGR of 5.2% from 2013 to reach ... market data tables and 15 figures spread through 135 ...
Breaking Medicine Technology:Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... PHOENIX, April 5, 2011 Express Scripts contributed more ... to an economic analysis of the company,s data by ... The economic impact study, presented today to ... company,s operations support 2,665 direct and indirect jobs in ...
... its first quarter 2011 earnings release (expected to be issued ... CVD ) is pleased to invite you to ... broadcast live over the Internet on Thursday, May 5, 2011 ... Webcast and Slide PresentationWhen: , Thursday, May 5, 2011, 9:00 ...
Cached Medicine Technology:Express Scripts Injects $226 Million Into Arizona Economy, Study Finds 2
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
(Date:9/2/2014)... Essen, Germany, September 2, 2014 In a ... Germany, researchers found that mild cognitive impairment (MCI) ... diabetes mellitus type 2. Interestingly, this strong association ... whereas in older participants (66-80 years) the association ... Journal of Alzheimer,s Disease . , The concept ...
(Date:9/2/2014)... Medex Analytic Services is delighted ... in Coral Springs, Fla. due to their greater than ... objectives for the 2014 year by distinguishing Medex in ... requested a higher level of service and professionalism in ... and the industry has responded.” , The location of ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
(Date:9/2/2014)... (HealthDay News) -- Melatonin supplements did not reduce delirium ... new study found. Many older hospital patients experience ... disruption of their normal sleep-wake cycle. A lack of ... to delirium, but there has been little research into ... study included 378 patients, average age 84, who had ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, Oct. 26 ... getting ready for the birth of their first child in 2001. ... small for its gestational age, his wife,s blood pressure had shot ... baby was no longer kicking. Losing the baby was devastating ...
... in Newfoundland have cracked the genetic code of a sudden ... have developed a unique prevention program in which people with ... history, are being implanted with internal cardiac defibrillators (ICDs) which ... discovery has led to a targeted genetic screening and individualized ...
... problems for children, with most kids experiencing at least one ... alone are in the billions of dollars. ... loss, speech problems and more severe infections that can spread ... have the same access to medical specialists and medicines. ...
... , MONDAY, Oct. 25 (HealthDay News) -- Having a ... the risk that if cancer develops it will spread to ... finding adds to the ongoing debate on whether PSA screenings ... treatment. "Our study shows that routine screening not only ...
... with prostate cancer treated with a specialized type ... have fewer gastrointestinal complications compared to patients treated ... a study presented November 1, 2010, at the ... Radiation Oncology (ASTRO). , "With survivors ...
... SEATTLE, Washington, October 25, 2010 The Life Sciences Discovery ... Seattle-based Omeros Corporation (NASDAQ: OMER) to discover, develop, and ... diseases. With successful generation of proceeds through partnering and ... outcome of the grant would be establishment of a ...
Cached Medicine News:Health News:Stillbirth Can Be Devastating, Unpredictable 2Health News:Stillbirth Can Be Devastating, Unpredictable 3Health News:Newfoundland researchers crack the genetic code of a sudden death cardiac killer 2Health News:Study finds race, ethnicity impact access to care for children with frequent ear infections 2Health News:Study finds race, ethnicity impact access to care for children with frequent ear infections 3Health News:PSA Test Reduces Risk of Spread if Prostate Cancer Strikes 2Health News:PSA Test Reduces Risk of Spread if Prostate Cancer Strikes 3Health News:Highly targeted radiation technique minimizes side effects of prostate cancer treatment 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 2Health News:Life Sciences Discovery Fund to support drug discovery, foster new R&D initiative 3
... For use with metered dose inhalers., ... medication from MDI canisters. Its versatile design ... ventilator circuit, in conjunction with an endotracheal ... oral inhalation. ACE may also be used ...
... Kit Nebulizer Small Volume Medication W/Adult ... Tubing Tee Adapter , ... times , ,Provide fine particles with ... particles) than conventional nebulizers, ,Our AirLife™ ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: